期刊文献+

紫杉醇对SGC-7901细胞增殖及survivin和Runx3表达的影响

The Effect of Taxol on Cell Proliferation and Expressions of Survivin and Runx3 in SGC-7901 Cell Line
原文传递
导出
摘要 [目的]探讨紫杉醇对SGC-7901胃癌细胞增殖及survivin和Runx3表达的影响。[方法]采用Western Blot方法检测胃癌细胞SGC-7901中survivin和Runx3表达,MTT方法检测紫杉醇对细胞增殖的抑制能力,分析survivin和Runx3表达与细胞增殖的关系。[结果]紫杉醇对SGC-7901的生长呈细胞毒作用;在一定剂量范围和时间点内,随着紫杉醇剂量的逐渐升高,SGC-7901细胞中survivin和Runx3表达呈剂量依赖性的上升趋势;在60ng/ml紫杉醇作用下,胃癌细胞中的survivin在24h内升高,随后下降;Runx3在48h内升高。[结论]紫杉醇可以诱导survivin和Runx3表达,在一定时间和剂量范围内对SGC-7901的抑制作用与survivin和Runx3表达呈正相关。
作者 孙健
机构地区 牡丹江医学院
出处 《中国肿瘤》 CAS 2011年第12期929-931,共3页 China Cancer
基金 牡丹江医学院科研项目(B2008-18)
  • 相关文献

参考文献9

  • 1王丽萍,钟皎,赵文艳,缪建华.紫杉醇联合顺铂双周疗法治疗晚期非小细胞肺癌的临床研究[J].中国药房,2009,20(11):839-841. 被引量:2
  • 2Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast canc.er patients [J]. Br J Cancer, 2007, 96(4): 639-645.
  • 3Okada E, Murai Y, Matsui K, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients [J]. Cancer Lett , 2001, 163(1): 109 -116 .
  • 4Ogasawara N, Tsukamoto T, Mi- zoshita T, et al. RUNX3 expression cor- relates with chief cell differentiation in human gastric cancers [J]. Histol Histooathol, 2009, 24(1): 31-40.
  • 5Loss with "Hsu PI, Hsieh "HL, Lee J, et al. of RUNX3 expression ton'elates differentiation, nodal metastasis, and poor prognosis of gastric cancer[J] Ann Surg Oncol, 2009,16(6): 1686-1694.
  • 6Miyagawa K, Sakakura C, Nakashima S, et al. l)own-regulation of RUNX1, RUNX3 and CBFbeta in hepa- tocellular carcinomas in an early stage of hepatocarcinogenesis[J]. Anticancer Res, 2006, 26(5B): 3633-3643.
  • 7Li QL Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer[J]. Cell, 2002, 109(1): 113-124.
  • 8陈小兵,罗素霞,肖毅军.紫杉醇联合卡培他滨治疗晚期胃癌临床观察[J].中华肿瘤防治杂志,2006,13(14):1115-1116. 被引量:18
  • 9Jemal A, Siegel R, Ward E, et al. Cancer statistics [J]. CA Cancer J Clin, 2007, 57(1): 43-66.

二级参考文献12

  • 1Trottia A, Colevas AD, Setser A, et al. CTCAE v 3.0 :development of a comprehensive grading system for the adverse efects of cancertreatment[J]. Semin Radiat Oncol,2003,13(3):176.
  • 2[美]罗兰T.斯基尔著,于世英译.癌症化疗手册[M].第6版.北京:科学出版社,2005:721,722.
  • 3Kroep JR, Smit EF, Giaccone G, et al. Pharmacology of the paclitaxel - cisplatin, gemcitabine - cisplatin, and paclitaxel- gemcitabine combinations in patients with advanced non- small cell lung cancer[J ] . Cancer Chemother Pha rmacol ,2006, 58( 4 ) : 509.
  • 4Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer[J]. Curr Treat Options Oncol,2007,8(1) :38.
  • 5Okamoto H, Watanabe K.Medical treatment for stage Ⅲ non - small - cell lung cancer (NSCLC) [J]. Gan To Kagaku Ryoho, 2007, 34(6) : 841.
  • 6Cascinu S,Graziano F,Cardarelli N,et al. Phase Ⅱ study of paclitaxel in pretreated advanced gastric cancer[J]. Anticancer Drugs, 1998,9(4) :307-310.
  • 7Rothenberg M L. Current status of capecitabine in the treatment of colorectal cancer[J]. Oncology, 2002,16 ( Suppl 14) : 16- 22.
  • 8Guan Z, Yu B, Wei Y. Capecitahine: A highLy effective and safe fist_Line chemotherapy in Chinese patients with metastatic colorectal carcinoma(MCRC)[J]. Proc Am Soc Clin ONCOI,2003,22(6):1277a.
  • 9王丽萍,赵文艳,曹洪富,钟皎.紫杉醇联合顺铂双周和周疗法治疗晚期非小细胞肺癌的疗效比较[J].药学与临床研究,2007,15(6):481-483. 被引量:2
  • 10钟皎,赵文艳,王丽萍.高效液相色谱法测定非小细胞肺癌患者血浆中紫杉醇浓度[J].中国医院药学杂志,2008,28(7):538-540. 被引量:11

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部